CD274 and small cell lung carcinoma: IMpower133 was the first major advance that demonstrated significant longer OS (12.3 vs. 10.3 months of median OS; 51.7% vs. 38.2% of 1-year OS, p = 0.007) and PFS (5.2 vs. 4.3 months of median PFS; 12.6% vs. 5.4% of 1-year PFS, p = 0.02) of combining atezolizumab (humanized monoclonal PD-L1 inhibitor) and chemotherapy than chemotherapy alone with placebo in ES-SCLC [4].